Back to search results
NCT07616167

This Study Evaluates the Use of a Data-driven Lower Limb Exoskeleton Controller for Stroke Rehabilitation.

Not Yet Recruiting
NAAges 18–80InterventionalTreatment
University of Michigan
~20 participants
Updated 2026-06-01 on ClinicalTrials.gov
What's tested:Unified Control Framework for Lower-Limb Powered OrthosisConventional Robotic Controller

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Walking Speed
Measured over Baseline (Week 0), Post-Intervention Phase 1 (Week 4), Post-Washout / Pre-Intervention Phase 2 (Week 8), and Post-Intervention Phase 2 (Week 12).
+1 more outcome measured

Conditions

Stroke

Explore related trials

Stroke

NCT07616167

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Rehabilitation Laboratory in the Ford Robotics Building on the University of Michigan North Campus

    Ann Arbor, Michiganno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Cohort 1: Able-Bodied Participants (Initial Validation)
Healthy young adults.
No history of neurological, orthopedic, or cardiovascular impairments affecting gait or balance.
Able to walk independently without assistive devices.
Individuals with a documented history of chronic stroke.
Persistent unilateral lower-limb motor impairment resulting in a pathological gait pattern (heterogeneous gait deficits).
Stable medical condition allowing for participation in intensive physical rehabilitation tasks.
Able to provide informed consent.

Exclusion

Severe cognitive or communication impairments that prevent the participant from following safety instructions or reporting discomfort.
Co-existing neurological conditions (other than stroke) that independently impair locomotion (e.g., Parkinson's disease, Multiple Sclerosis).
Severe lower-limb joint contractures or orthopedic conditions that mechanically restrict the safe range of motion of the robotic orthosis.
Skin breakdowns, open wounds, or severe unhealed lesions at the contact points where the powered orthosis interfaces with the lower limbs.
Any medical contraindication to intensive walking exercise or treadmill training (e.g., unstable angina, severe unmanaged cardiovascular disease).

What this trial measures

  • Walking SpeedBaseline (Week 0), Post-Intervention Phase 1 (Week 4), Post-Washout / Pre-Intervention Phase 2 (Week 8), and Post-Intervention Phase 2 (Week 12).

    A standardized clinical assessment used to determine short-distance walking speed over a 10-meter course. This metric evaluates the preliminary clinical efficacy of the unified control framework compared to the conventional controller in chronic stroke survivors.

  • Functional Mobility and BalanceBaseline (Week 0), Post-Intervention Phase 1 (Week 4), Post-Washout / Pre-Intervention Phase 2 (Week 8), and Post-Intervention Phase 2 (Week 12).

    A clinical performance-based measure used to assess dynamic balance, turning agility, and functional mobility. The test measures the time (in seconds) taken for a participant to rise from a chair, walk 3 meters, turn around, walk back, and sit down.